CytoDyn Inc. (CYDY)
OTCMKTS · Delayed Price · Currency is USD
0.21372
+0.00372 (1.77%)
At close: Sep 18, 2026
CytoDyn Employees
CytoDyn had 14 employees as of May 31, 2026. The number of employees increased by 1 or 7.69% compared to the previous year.
Employees
14
Change (1Y)
1
Growth (1Y)
7.69%
Revenue / Employee
n/a
Profits / Employee
-$3,155,714
Market Cap
306.91M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| May 31, 2026 | 14 | 1 | 7.69% |
| May 31, 2025 | 13 | 4 | 44.44% |
| May 31, 2024 | 9 | -3 | -25.00% |
| May 31, 2023 | 12 | -11 | -47.83% |
| May 31, 2022 | 23 | -1 | -4.17% |
| May 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| May 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| May 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| May 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| May 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Sangamo Therapeutics | 142 |
| Northwest Biotherapeutics | 105 |
| Silence Therapeutics | 88 |
| Vaxart | 65 |
| Nuo Therapeutics | 10 |
CytoDyn News
- 2 days ago - CytoDyn Transcript: Life Sciences Virtual Investor Forum Conference - Transcripts
- 5 days ago - CytoDyn Inc. to Present at the Life Sciences Investor Forum on September 17th - GlobeNewsWire
- 19 days ago - CytoDyn Closes $16.5 Million Financing to Fund Continued Development of Leronlimab - GlobeNewsWire
- 20 days ago - CytoDyn Annual report: Q4 2026 - Filings
- 3 months ago - CytoDyn Announces First Patient Dosed in Phase 2a Study in Collaboration with Weill Cornell Medicine Evaluating Leronlimab in Alzheimer's Disease - GlobeNewsWire
- 3 months ago - Natera, CytoDyn collaborate to advance ctDNA-guided development - TheFly
- 4 months ago - CytoDyn Transcript: 16th Annual LD Micro Invitational Conference - Transcripts
- 4 months ago - CytoDyn to Present at the LD Micro Invitational XVI - GlobeNewsWire